THOUSAND OAKS, Calif.,
Dec. 15, 2015 /PRNewswire/
-- Amgen (NASDAQ: AMGN) today announced that its Board of
Directors declared a $1.00 per share
dividend for the first quarter of 2016. The dividend will be paid
on March 8, 2016, to all stockholders
of record as of the close of business on Feb. 16, 2016. This represents a 27 percent
increase from that paid in each of the previous four quarters.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Forward-Looking Statements
This news release contains
forward-looking statements that involve significant risks and
uncertainties, including those discussed below and others that can
be found in our Form 10-K for the year ended Dec. 31, 2014, and in any subsequent periodic
reports on Form 10-Q and Form 8-K. We are providing this
information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our
results may be affected by our ability to successfully market both
new and existing products domestically and internationally,
clinical and regulatory developments (domestic or foreign)
involving current and future products, sales growth of recently
launched products, competition from other products (domestic or
foreign) and difficulties or delays in manufacturing our
products. In addition, sales of our products are affected by
reimbursement policies imposed by third-party payers, including
governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments
and domestic and international trends toward managed care and
healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and
others' regulations and reimbursement policies may affect the
development, usage and pricing of our products. Furthermore,
our research, testing, pricing, marketing and other operations are
subject to extensive regulation by domestic and foreign government
regulatory authorities. We or others could identify safety,
side effects or manufacturing problems with our products after they
are on the market. Our business may be impacted by government
investigations, litigation and product liability claims. If
we fail to meet the compliance obligations in the corporate
integrity agreement between us and the U.S. government, we could
become subject to significant sanctions. Further, while we
routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors.
We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and
future products and limits on supply may constrain sales of certain
of our current products and product candidate development. In
addition, we compete with other companies with respect to some of
our marketed products as well as for the discovery and development
of new products. Discovery or identification of new product
candidates cannot be guaranteed and movement from concept to
product is uncertain; consequently, there can be no guarantee that
any particular product candidate will be successful and become a
commercial product. Further, some raw materials, medical
devices and component parts for our products are supplied by sole
third-party suppliers. Our efforts to integrate the
operations of companies we have acquired may not be
successful. Cost saving initiatives may result in us
incurring impairment or other related charges on our assets. We may
experience difficulties, delays or unexpected costs and not achieve
anticipated benefits and savings from our ongoing restructuring
plan. Our business performance could affect or limit the
ability of our Board of Directors to declare a dividend or our
ability to pay a dividend or repurchase our common stock.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Kristen Neese, 805-313-8267
(media)
Arvind Sood, 805-447-1060
(investors)
Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-announces-27-percent-increase-in-2016-first-quarter-dividend-300193308.html
SOURCE Amgen